Ifosfamide | CAS# 3778-73-2 APExBIO 貨號A2097 Purity = 98.65%
| 代理廠牌： |  |
| 原廠連結： | |
| 相關下載： |
特點
DNA烷基化劑/交聯劑- Ifosfamide
Ifosfamide | CAS# 3778-73-2 APExBIO 貨號A2097 Purity = 98.65%
Cytostatic agent
是一種烷基化化療劑，具有抗多種腫瘤的活性。異環磷醯胺(Ifosfamide)是一種細胞抑制劑，其結構與環磷醯胺(cyclophosphamide)相關。
| Storage | Store at -20°C |
| M.Wt | 261.09 |
| Cas No. | 3778-73-2 |
| Formula | C7H15Cl2N2O2P |
| Solubility | ≥13.05 mg/mL in DMSO; ≥22 mg/mL in H2O; ≥61.5 mg/mL in EtOH |
| Chemical Name | N,3-bis(2-chloroethyl)-2-oxo-1,3,2λ5-oxazaphosphinan-2-amine |
| SDF | Download SDF |
| Canonical SMILES | C1CN(P(=O)(OC1)NCCCl)CCCl |
| Shipping Condition | Small Molecules with Blue Ice, Modified Nucleotides with Dry Ice. |
| General tips | We do not recommend long-term storage for the solution, please use it up soon. |
APExBIO台灣代理商
APExBIO提供優質的胜肽和生物分析試劑，廣泛產品線如Protease、Chromatin/Epigenetics表觀遺傳學、MAPK Signal、DNA Damege/DNA repair、細胞凋亡、腫瘤生物學、Stem cell等研究領域， 還提供定制的服務，包括多肽合成，抗體的生產和檢測的發展。產品線DNA/RNA prep kit、Drug Screening panel、Bioactive peptides、Growth factors、Biotinylation Reagents、tag peptides、amino Acids、Growth factors等。APExBIO產品質量都伴隨著證書的分析，高效液相色譜，質譜，和HMNR數據。
| 品項 | CAS# | #貨號 | 應用 |
| Z-VAD-FMK | CAS# 187389-52-2 | 貨號 A1902 |
Proteases ICE-like proteases |
| TAPI-1 | CAS#171235-71-5 | 貨號 B4686 |
Proteases TACE/ADAM17 inhibitor Product Citation+3 |
| Talabostat mesylate | CAS# 150080-09-4 | 貨號B3941 |
Proteases DPP4 二肽基肽酶特異性抑制劑 |
| Z-IETD-FMK | CAS# 210344-98-2 | 貨號B3232 | inhibitor of caspase 8 |
| Cisplatin | CAS# 15663-27-1 | 貨號A8321 | 高效、廣譜的化療藥物 |
| 17-DMAG (Alvespimycin) HCl | CAS#467214-21-7 | 貨號A2213 | Hsp90 inhibitor |
| CA-074 Me | CAS# 147859-80-1 | 貨號A8239 | Cathepsin B inhibitor |
| VX-765 | CAS# 273404-37-8 | 貨號A8238 | Caspase-1 inhibitor |
| A4108 | Resminostat (RAS2410) | 864814-88-0 | 98.00% | Potent HDAC inhibitor |
| A4110 | MLN8237 (Alisertib) | 1028486-01-2 | 98.77% | Aurora A Kinase inhibitor, Potent and selective |
| A4111 | VX-680 (MK-0457,Tozasertib) | 639089-54-6 | 99.93% | Aurora kinase inhibitor |
| A4112 | Barasertib (AZD1152-HQPA) | 722544-51-6 | 98.25% | Aurora Kinase B inhibitor, Potent and selective |
| A4113 | ZM 447439 | 331771-20-1 | 98.80% | Aurora Kinase inhibitor,potent and selective |
| A4114 | MLN8054 | 869363-13-3 | 97.64% | Aurora A inhibitor |
| A4115 | JNJ-7706621 | 443797-96-4 | 98.11% | Potent CDK/Aurora kinase inhibitor |
| A4116 | Danusertib (PHA-739358) | 827318-97-8 | 99.39% | Pan-aurora kinase inhibitor |
| A4117 | AT9283 | 896466-04-9 | 99.29% | Aurora kinase/JAK inhibitor |
| A4118 | Hesperadin | 422513-13-1 | 98.29% | Aurora B kinase inhibitor |
| A4119 | AMG-900 | 945595-80-2 | 98.99% | Aurora kinase inhibitor |
| A4120 | MK-5108 (VX-689) | 1010085-13-8 | 96.91% | Aurora-A kinase inhibitor,highly selective |
| A4121 | SNS-314 Mesylate | 1146618-41-8 | 99.94% | Aurora A/B/C kinases inhibitor, potent and selective |
| A4122 | PHA-680632 | 398493-79-3 | 98.53% | Aurora kinase inhibitor,novel and potent |
| A4123 | KW 2449 | 1000669-72-6 | 99.94% | Multikinase inhibitor |
| A4124 | TAK-901 | 934541-31-8 | 98.00% | Novel Aurora A/B inhibitor |
| A4125 | CYC116 | 693228-63-6 | 98.71% | Potent Aurora A/B inhibitor |
| A4126 | Aurora A Inhibitor I | 1158838-45-9 | 98.83% | Aurora A inhibitor |
| A4127 | GSK1070916 | 942918-07-2 | 98.00% | Aurora B/C inhibitor |
| A4128 | PF-03814735 | 942487-16-3 | 98.00% | Aurora A/B inhibitor |
| A4129 | ENMD-2076 L-(+)-Tartaric acid | 1291074-87-7 | 99.36% | Aurora kinases inhibitor |
| A4130 | ENMD-2076 | 934353-76-1 | 98.78% | Selective Aurora A/Flt3 inhibitor |
| A4132 | CCT137690 | 1095382-05-0 | 98.00% | Aurora A/B/C inhibitor |
| A4135 | Tofacitinib (CP-690550) Citrate | 540737-29-9 | 99.64% | Potent JAK inhibitor |
| A4136 | TG101348 (SAR302503) | 936091-26-8 | 99.39% | JAK-2 inhibitor,potent and selective |
| A4137 | AZD1480 | 935666-88-9 | 99.31% | JAK2 inhibitor,ATP-competitive and novel |
| A4138 | Tofacitinib (CP-690550,Tasocitinib) | 477600-75-2 | 99.94% | Janus kinase inhibitor |
| A4139 | AG-490 | 133550-30-8 | 99.76% | JAK2/EGFR inhibitor |
| A4140 | WP1066 | 857064-38-1 | 99.84% | JAK2/STAT3 inhibitor,cell-permeable |
| A4141 | Baricitinib (LY3009104, INCB028050) | 1187594-09-7 | 98.06% | JAK1/JAK2 inhibitor,selective orally bioavailable |
| A4143 | CYT387 | 1056634-68-4 | 98.70% | JAK-1/-2 inhibitor,ATP competitive |
| A4144 | AZ 960 | 905586-69-8 | 98.00% | JAKs inhibitor |
| A4145 | TG101209 | 936091-14-4 | 99.46% | JAK2/3 inhibitor |
| A4146 | CEP-33779 | 1257704-57-6 | 98.00% | JAK2 inhibitor,highly selective |
| A4147 | LY2784544 | 1229236-86-5 | 98.00% | JAK2 inhibitor,highly potent and selective |
| A4148 | NVP-BSK805 2HCl | 1092499-93-8 (free base) | 99.23% | JAK2 inhibitor |
| A4149 | S-Ruxolitinib (INCB018424) | 941685-37-6 | 99.34% | JAK1/2 inhibitor,potent and selective |
| A4150 | WHI-P154 | 211555-04-3 | 99.19% | JAK3 inhibitor |
| A4151 | ZM 39923 HCl | 1021868-92-7 | 99.91% | JAK3 inhibitor,potent and selective |
| A4152 | BMS-911543 | 1271022-90-2 | 98.41% | JAK2 inhibitor,selective small molecule |
| A4153 | BMN 673 | 1207456-01-6 | 99.26% | Potent PARP inhibitor |
| A4154 | Olaparib (AZD2281, Ku-0059436) | 763113-22-0 | 99.80% | Potent PARP1/PARP2 inhibitor |
| A4156 | Rucaparib (AG-014699,PF-01367338) | 459868-92-9 | 98.46% | Potent PARP inhibitor |
| A4157 | Iniparib (BSI-201) | 160003-66-7 | 99.08% | PARP1 inhibitor,intravenously adminsitered |
| A4158 | AG-14361 | 328543-09-5 | 99.17% | Potent PARP1 inhibitor |
| A4159 | PJ34 hydrochloride | 344458-15-7 | 99.54% | PARP inhibitor,potent and cell-permeable |
| A4160 | A-966492 | 934162-61-5 | 99.03% | PARP-1/-2 inhibitor, highly potent |
| A4161 | 3-aminobenzamide | 3544-24-9 | 99.66% | Potent PARP inhibitor |
| A4163 | UPF 1069 | 1048371-03-4 | 98.00% | Selective PARP2 inhibitor |
| A4164 | AZD2461 | 1174043-16-3 | 98.00% | Novel PARP inhibitor |
| A4166 | EPZ5676 | 1380288-87-8 | 99.28% | DOT1L inhibitor,potent and SAM competitive |
| A4167 | SGC 0946 | 1561178-17-3 | 99.65% | DOT1L inhibitor,highly potent and selective |
| A4168 | Entacapone | 130929-57-6 | 99.28% | COMT inhibitor |
| A4170 | EPZ004777 | 1338466-77-5 | 99.43% | DOT1L inhibitor |
| A4171 | EPZ005687 | 1396772-26-1 | 98.66% | EZH2 inhibitor,potent and selective |
| A4176 | Thioguanine | 154-42-7 | 98.18% | Purine antimetabolite |
| A4180 | SRT1720 HCl | 1001645-58-4 | 99.52% | SIRT1 activator |
| A4181 | EX 527 (SEN0014196) | 49843-98-3 | 99.71% | SIRT1 inhibitor |
| A4182 | Resveratrol | 501-36-0 | 99.94% | SIRT1 activator |
| A4183 | Sirtinol | 410536-97-9 | 98.00% | SIRT inhibitor |
| A4184 | PFI-1 (PF-6405761) | 1403764-72-6 | 97.20% | BET inhibitor |
| A4186 | Bromosporine | 1619994-69-2 | 98.00% | Bromodomain inhibitor,non-selective |
| A4187 | FG-4592 (ASP1517) | 808118-40-3 | 99.92% | HIF prolyl-hydroxylase inhibitor |
| A4188 | 2-Methoxyestradiol (2-MeOE2) | 362-07-2 | 99.00% | Apoptotic, antiproliferative and antiangiogenic agent |
| A4189 | IOX2(Glycine) | 931398-72-0 | 98.10% | HIF-1α prolyl hydroxylase-2 (PHD2) inhibitor |
| A4190 | GSK J4 HCl | 1373423-53-0(free base) | 98.00% | Inhibitor of H3K27 demethylase JMJD3,potent and cell-permeable |
| A4191 | GSK J1 | 1373422-53-7 | 99.50% | H3K27 demethylase JMJD3 inhibitor |
| A4192 | SGI-1776 free base | 1025065-69-3 | 99.19% | Pim kinase inhibitor,ATP-competitive |
| A4193 | SMI-4a | 438190-29-5 | 99.76% | Potent Pim inhibitor |
| A4194 | Obatoclax mesylate (GX15-070) | 803712-79-0 | 98.49% | Potent Bcl-2 inhibitor |
| A4199 | Sabutoclax | 1228108-65-3 | 98.00% | pan-Bcl-2 inhibitor |
| A4200 | Apogossypolone (ApoG2) | 886578-07-0 | 98.00% | Bcl-2 inhibitor,nonpeptidic small molecule |
| A4202 | RITA (NSC 652287) | 213261-59-7 | 99.53% | Mdm2-p53 interaction and p53 ubiquitination blocking |
| A4203 | Tenovin-1 | 380315-80-0 | 99.90% | SIRT2 inhibitor, activates p53 |
| A4204 | JNJ-26854165 (Serdemetan) | 881202-45-5 | 98.35% | P53 activator, blocking Mdm2-p53 interaction |
| A4206 | Pifithrin-α (PFTα) | 63208-82-2 | 98.16% | p53 inhibitor |
| A4208 | NSC 319726 | 71555-25-4 | 98.00% | Reactivator of mutant p53 |
| A4209 | NSC 207895 (XI-006) | 58131-57-0 | 98.00% | MDMX inhibitor,anti-cancer agent |
| A4210 | Bay 11-7821 (BAY 11-7082) | 19542-67-7 | 99.91% | IKK/NF-κB/TNFα inhibitor |
| A4211 | Lenalidomide (CC-5013) | 191732-72-6 | 98.66% | Antineoplastic agent,inhibits angiogenesis |
| A4212 | Pomalidomide (CC-4047) | 19171-19-8 | 98.46% | Immunomodulator,antumor/anti-angiogenic |
| A4213 | Necrostatin-1 | 4311-88-0 | 99.88% | RIP1 inhibitor |
| A4216 | Thalidomide | 50-35-1 | 99.21% | Immunomodulatory agent,sedative drug,angiogenesis inhibitor |
| A4217 | QNZ (EVP4593) | 545380-34-5 | 99.41% | Potent NF-κB inhibitor |
| A4219 | Birinapant (TL32711) | 1260251-31-7 | 98.13% | Potent XIAP/cIAP1 antagonist |
| A4221 | YM155 | 781661-94-7 | 99.60% | Survivin suppressant,apoptosis inhibitor |
| A4224 | GDC-0152 | 873652-48-3 | 99.00% | IAP antagonist,potent amd samll-molecule |
| A4227 | Tipifarnib (Zarnestra) | 192185-72-1 | 99.18% | Farnesyltransferase inhibitor,potent and specific |
| A4228 | Nutlin-3 | 890090-75-2 | 98.35% | MDM2 antagonist,inhibits MDM2-p53 interaction |
| A4230 | NSC 66811 | 6964-62-1 | 98.00% | MDM2 inhibitor |
| A4232 | Cyclophosphamide monohydrate | 6055-19-2 | 98.00% | alkylating, cytotoxic agent,antitumor activity |
| A4233 | Methylprednisolone | 83-43-2 | 99.31% | Apoptosis inducer,GR agonist |
| A4234 | TW-37 | 877877-35-5 | 98.13% | Bcl-2 inhibitor, inhibits Bcl-2,Bcl-XL and Mcl-1 |
| A4237 | Amuvatinib (MP-470, HPK 56) | 850879-09-3 | 99.91% | Tyrosine kinase inhibitor |
| A4240 | Abiraterone | 154229-19-3 | 99.30% | Potent CYP17 inhibitor |
| A4300 | GW9662 | 22978-25-2 | 99.25% | PPARγ antagonist |
| A4301 | T0070907 | 313516-66-4 | 99.88% | Human PPARγ antagonist,potent and selective |
| A4302 | Rosiglitazone maleate | 155141-29-0 | 99.15% | PPARγ agonist,high-affinity and selective,potent insulin sensitizer |
| A4303 | GSK3787 | 188591-46-0 | 99.73% | PPARβ/δ antagonist,novel and irreversible |
| A4304 | Rosiglitazone | 122320-73-4 | 99.80% | Potent PPARγ agonist |
| A4305 | WY-14643 (Pirinixic Acid) | 50892-23-4 | 99.87% | PPARα agonist,selective and highly potent |
| A4306 | Ciprofibrate | 52214-84-3 | 98.88% | PPARα agonist |
| A4307 | GW0742 | 317318-84-6 | 99.64% | PPARδ/β agonist,potent and selective |
| A4308 | Alizarin | 72-48-0 | 98.03% | Chelator for calcium,used to stain calcium deposites,Alizarin complexone is used for bone staining to study bone remodeling |
| A4309 | GW501516 | 317318-70-0 | 98.27% | PPARδ agonist,selective and potent |
| A4310 | Rosiglitazone HCl | 302543-62-0 | 99.31% | PPARγ agonist |
| A4311 | PF-4981517 | 1390637-82-7 | 98.00% | CYP3A4 inhibitor,potent and selective |
| A4313 | Cobicistat (GS-9350) | 1004316-88-4 | 99.94% | Selective CYP3A inhibitor |
| A4316 | Ketoconazole | 65277-42-1 | 99.48% | Inhibitor of cyclosporine oxidase and testosterone 6 beta-hydroxylase |
| A4317 | Apremilast (CC-10004) | 608141-41-9 | 98.98% | PDE4 inhibitor |
| A4318 | Avasimibe | 166518-60-1 | 99.66% | ACAT inhibitor,orally bioavailable |
| A4319 | Roflumilast | 162401-32-3 | 99.08% | PDE-4 inhibitor |
| A4320 | Voriconazole | 137234-62-9 | 99.96% | CYP51 inhibitor |
| A4321 | Sildenafil Citrate | 171599-83-0 | 99.63% | Treat erectile dysfunction and PAH |
| A4322 | Clarithromycin | 81103-11-9 | 99.39% | CYP3A inhibitor, potent |
| A4323 | Vardenafil HCl Trihydrate | 330808-88-3 | 99.63% | PDE5 inhibitor, potent and selective |